Latest news with #Glaukos
Yahoo
3 days ago
- Business
- Yahoo
Those who invested in Glaukos (NYSE:GKOS) three years ago are up 120%
While Glaukos Corporation (NYSE:GKOS) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 21% in the last quarter. In contrast, the return over three years has been impressive. Indeed, the share price is up a very strong 120% in that time. So the recent fall in the share price should be viewed in that context. If the business can perform well for years to come, then the recent drop could be an opportunity. With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Because Glaukos made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually desire strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. Over the last three years Glaukos has grown its revenue at 12% annually. That's pretty nice growth. It's fair to say that the market has acknowledged the growth by pushing the share price up 30% per year. It's hard to value pre-profit businesses, but it seems like the market has become a lot more optimistic about this one! It would be worth thinking about when profits will flow, since that milestone will attract more attention. The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image). Glaukos is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. Given we have quite a good number of analyst forecasts, it might be well worth checking out this free chart depicting consensus estimates. Investors in Glaukos had a tough year, with a total loss of 16%, against a market gain of about 13%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 15% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. You might want to assess this data-rich visualization of its earnings, revenue and cash flow. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
3 days ago
- Business
- Yahoo
Those who invested in Glaukos (NYSE:GKOS) three years ago are up 120%
While Glaukos Corporation (NYSE:GKOS) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 21% in the last quarter. In contrast, the return over three years has been impressive. Indeed, the share price is up a very strong 120% in that time. So the recent fall in the share price should be viewed in that context. If the business can perform well for years to come, then the recent drop could be an opportunity. With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Because Glaukos made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually desire strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. Over the last three years Glaukos has grown its revenue at 12% annually. That's pretty nice growth. It's fair to say that the market has acknowledged the growth by pushing the share price up 30% per year. It's hard to value pre-profit businesses, but it seems like the market has become a lot more optimistic about this one! It would be worth thinking about when profits will flow, since that milestone will attract more attention. The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image). Glaukos is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. Given we have quite a good number of analyst forecasts, it might be well worth checking out this free chart depicting consensus estimates. Investors in Glaukos had a tough year, with a total loss of 16%, against a market gain of about 13%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 15% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. You might want to assess this data-rich visualization of its earnings, revenue and cash flow. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
The Herald Scotland
6 days ago
- Health
- The Herald Scotland
Open your eyes to revolutionary new treatment for glaucoma in Scotland
Damage to the optic nerve is irreversible so early diagnosis is crucial. Lowering the eye pressure is the most effective way to control glaucoma and the only treatment. Glaucoma can be difficult to detect without an eye test as most people experience no symptoms in the early stages. Regular eye checks are vital and particularly the glaucoma checks that form part of normal sight tests. GLAUCOMA TREATMENT ONCE diagnosed, the most common treatment for glaucoma is prescription eye drops, which may need to be applied up to three times a day. Therefore compliance can become an issue, potentially limiting the efficacy of the treatment. An alternative treatment is Trabecular micro-bypass surgery, which involves implanting micro stents into the eye such as iStent® inject W. Research has shown that this procedure provides an opportunity for patients to experience a better quality of life, the primary goal of glaucoma management. The surgery can improve their visual function and ease their fears about glaucoma-related sight loss. iStent inject® W comprises of microscopic 0.36mm stents which are implanted into the eye. The surgery is as safe as cataract surgery alone and can be performed under needleless anaesthetic at the same time as cataract surgery or as a separate procedure. The stents work by helping to restore the eye's natural fluid outflow which in turn reduces eye pressure. An international study found that 72% of patients treated with iStent® inject no longer required glaucoma medication after 12 months. To date, iStent inject® is supported by over five years of published data on its safety and efficacy. Additionally, more than 300 peer-reviewed studies on iStent technologies have been published, with over one million eyes treated worldwide. David Kinloch, 65, from Glasgow recently had iStents and cataract surgery with Mr Mamun Rahman. (Image: Mr Mamun Rahman is a Consultant Ophthalmic Surgeon at Eye Care Scotland, Glasgow) He was full of praise, stating: 'Absolutely delighted with the results of my eye operations. Glaucoma is a serious hereditary problem in my family, coupled with severe myopia and latterly cataracts. Mr Rahman inserted stents, removed my cataracts and replaced my myopic lenses. 'For the first time in 50 years I can see without aids and my ocular pressure has reduced to safe levels. To say I am delighted is an understatement. A fantastic surgeon with a great team and to cap it all a lovely manner and just a nice friendly person.' For more details, visit ■ iStent inject® W is a registered trademark of Glaukos corporation
Yahoo
08-04-2025
- Business
- Yahoo
Should You Invest in Geron Corporation (GERN)?
ClearBridge Investments, an investment management company, released its 'ClearBridge Small Cap Growth Strategy' first quarter 2025 investor letter. A copy of the letter can be downloaded here. The stock market performance in the first quarter of 2025 was volatile, following the initial 'animal spirits' post-election rally. The strategy surpassed its benchmark with the support of new ideas, reorienting efforts, and tailwinds in several industries despite volatility and uncertainty. Given the pace of major policy changes, the firm expects ongoing volatility as the effects of tariffs and policymaking have clouded visibility. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first quarter 2025 investor letter, ClearBridge Small Cap Growth Strategy emphasized stocks such as Geron Corporation (NASDAQ:GERN). Geron Corporation (NASDAQ:GERN) is a commercial-stage biopharmaceutical company. The one-month return of Geron Corporation (NASDAQ:GERN) was -11.88%, and its shares lost 58.89% of their value over the last 52 weeks. On April 7, 2025, Geron Corporation (NASDAQ:GERN) stock closed at $1.41 per share with a market capitalization of $898.035 million. ClearBridge Small Cap Growth Strategy stated the following regarding Geron Corporation (NASDAQ:GERN) in its Q1 2025 investor letter: "We continued to generate a number of compelling new ideas, adding five new investments that we still held at quarter end: Glaukos, Rocket Lab USA, Karman Holdings (through its IPO), Archrock, Hims & Hers and Geron Corporation (NASDAQ:GERN). A close-up of a laboratory technician in a laboratory, measuring a newly developed biopharmaceutical drug. Geron Corporation (NASDAQ:GERN) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 46 hedge fund portfolios held Geron Corporation (NASDAQ:GERN) at the end of the fourth quarter compared to 29 in the third quarter. While we acknowledge the potential of Geron Corporation (NASDAQ:GERN) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. We covered Geron Corporation (NASDAQ:GERN) in another article, where we shared the list of top penny stocks that will skyrocket. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
08-04-2025
- Business
- Yahoo
Here's Why Hims & Hers Health (HIMS) is Growing Revenue And Profitability
ClearBridge Investments, an investment management company, released its 'ClearBridge Small Cap Growth Strategy' first quarter 2025 investor letter. A copy of the letter can be downloaded here. The stock market performance in the first quarter of 2025 was volatile, following the initial 'animal spirits' post-election rally. The strategy surpassed its benchmark with the support of new ideas, reorienting efforts, and tailwinds in several industries despite volatility and uncertainty. Given the pace of major policy changes, the firm expects ongoing volatility as the effects of tariffs and policymaking have clouded visibility. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first quarter 2025 investor letter, ClearBridge Small Cap Growth Strategy emphasized stocks such as Hims & Hers Health, Inc. (NYSE:HIMS). Hims & Hers Health, Inc. (NYSE:HIMS) offers a telehealth platform that connects consumers to licensed healthcare professionals. The one-month return of Hims & Hers Health, Inc. (NYSE:HIMS) was -19.99%, and its shares gained 90.86% of their value over the last 52 weeks. On April 7, 2025, Hims & Hers Health, Inc. (NYSE:HIMS) stock closed at $27.77 per share with a market capitalization of $6.17 billion. ClearBridge Small Cap Growth Strategy stated the following regarding Hims & Hers Health, Inc. (NYSE:HIMS) in its Q1 2025 investor letter: "We continued to generate a number of compelling new ideas, adding five new investments that we still held at quarter end: Glaukos, Rocket Lab USA, Karman Holdings (through its IPO), Archrock, Hims & Hers Health, Inc. (NYSE:HIMS) and Geron. A nurse in a telehealth platform talking with a patient on video call for consultation. Hims & Hers Health, Inc. (NYSE:HIMS) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 38 hedge fund portfolios held Hims & Hers Health, Inc. (NYSE:HIMS) at the end of the fourth quarter compared to 31 in the third quarter. Hims & Hers Health, Inc.'s (NYSE:HIMS) revenue was $481 million for the fourth quarter representing an increase of 95% year-over-year. While we acknowledge the potential of Hims & Hers Health, Inc. (NYSE:HIMS) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. We covered Hims & Hers Health, Inc. (NYSE:HIMS) in another article, where we shared the list of most shorted stocks in 2025. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
